BCRX BioCryst Pharmaceuticals, Inc. - Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · biocryst.com

8.015USD-1.90%Mkt Cap: 2.09B $P/E: —Today

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuramini…

Industry Peers

Drug Manufacturers - Specialty & Generic

Takeda Pharmaceutical Company Limited

$56.90BUSD

TEVA

Teva Pharmaceutical Industries Limited

United Therapeutics Corporation - Common Stock

$23.23BUSDP/E 19.4

VTRS

Viatris Inc. - Common Stock

$20.22BUSD

SOBI

Swedish Orphan Biovitrum AB (publ)

$14.14BUSDP/E 110.6

NBIX

Neurocrine Biosciences, Inc. - Common Stock

Elanco Animal Health Incorporated

$11.25BUSD

RDY

Dr. Reddy's Laboratories Limited

Amneal Pharmaceuticals, Inc. - Class A Common Stock

$7.07BUSDP/E 42.3

ALKS

Alkermes plc - Ordinary Shares

$7.00BUSDP/E 109.9

HIMS

Hims & Hers Health, Inc.

$6.92BUSD

LNTH

Lantheus Holdings, Inc. - Common Stock

$6.53BUSDP/E 23.9

KNSA

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

$5.83BUSDP/E 76.6

INDV

Indivior Pharmaceuticals, Inc. - Common Stock

$4.21BUSDP/E 12.8

Key Statistics

Company

Market Cap2.09B USD

Enterprise Value2.57B USD

Revenue (TTM)940.61M USD

Gross Profit855.76M USD

Net Income (TTM)263.86M USD

Revenue/Share4.10 USD

Last Price8.015 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees435

CountryUS

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)8.69

PEG9.39

EV/EBITDA5.94

EV/Revenue2.73

P/S2.22

P/B-4.59

EPS (TTM)-1.40

EPS (Forward)0.94

52W Range

6.00039% of range11.22

52W High11.22 USD

52W Low6.000 USD

Profitability

Gross Margin97.82%

Oper. Margin45.12%

EBITDA Margin46.04%

Profit Margin30.16%

ROE-221.45%

ROA51.32%

Growth

Revenue Growth33.60%

Earnings Growth1400.00%

Cash Flow & Leverage

Operating CF347.37M USD

CapEx (TTM)2.47M USD

FCF Margin34.41%

FCF Yield15.50%

Net Debt484.07M USD

Net Debt/EBITDA1.12

Balance Sheet

Debt/Equity-3.68

Current Ratio2.32

Quick Ratio2.22

Book Value/Sh-1.78 USD

Cash/Share1.38 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.5 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)20.73 USD

Upside (mean)+158.6%

Target Range11.00 USD – 32.00 USD

11.00+158.6% to mean32.00

# Analysts11

Ownership

Shares Out.255.54M

Float222.32M

Insiders1.28%

Institutions105.27%

Short Interest

Short Ratio9.8d

Short % Float13.75%

Short % Out.13.65%

Shares Short34.87M

Short (prev mo.)32.94M

Technical

SMA 509.223 (-13.1%)

SMA 2008.681 (-7.7%)

Beta0.56

S&P 52W Chg14.58%

Avg Vol (30d)4.67M

Avg Vol (10d)5.54M

Technical Indicators

RSI (14)36.8

MACD-0.3240

MACD Signal-0.2936

MACD Hist.-0.0304

BB Upper9.998 USD

BB Middle8.707 USD

BB Lower7.417 USD

BB Width29.63%

ATR (14)0.3659 USD

Vol Ratio (20d)1.14x